Shuddha Guggulu
Shuddha Guggulu Price range: $ 49,00 through $ 292,00
Back to products
Silagra
Silagra Price range: $ 50,00 through $ 206,00

Sibelium

Price range: $ 41,00 through $ 55,00

Sibelium is a specialized medication primarily utilized for the effective prophylaxis of migraine headaches. By acting as a selective calcium antagonist, it helps reduce both the frequency and severity of recurring migraine attacks. This treatment is also highly beneficial for managing symptoms of vestibular disorders, including persistent vertigo and dizziness. The medication is formulated to provide long-term relief and improve the overall quality of life for individuals dealing with these chronic conditions. Each dose contains flunarizine, ensuring a consistent and reliable approach to neurological symptom management.

Active substance: Flunarizine
SKU: Sibelium Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Sibelium contains flunarizine dihydrochloride, a difluorinated piperazine derivative classified pharmacologically as a selective calcium entry blocker with additional histamine H1-receptor antagonist properties. Unlike traditional calcium channel blockers that primarily act on vascular smooth muscle, flunarizine selectively inhibits the overload of calcium ions into cells during state-dependent cellular hypoxia or excessive neuronal stimulation.

Within the United States healthcare market, flunarizine is dispensed in accordance with applicable federal and state regulations. Patients prescribed or evaluating this agent should review its pharmacological profile, dosing paradigms, potential adverse drug events, and relevant clinical precautions.

Property Description
Active ingredient (INN) Flunarizine dihydrochloride
Therapeutic class Selective calcium channel antagonist / Antivertigo agent
Dosage form Oral capsules / Oral tablets
Route of administration Oral
Primary purpose Migraine prophylaxis and vestibular symptom management
Prescription status Dispensed in accordance with applicable federal and state regulations

Clinical Overview and Pharmacological Profile

Drug Overview and Mechanism

How the drug works

The primary mechanism of action of flunarizine involves the selective prevention of intracellular calcium overload. Under pathophysiological conditions such as cellular hypoxia, ischemia, or excessive neuronal depolarization, an abnormal influx of extracellular calcium ions occurs across cell membranes. Flunarizine blocks these trans-membrane calcium currents without interfering with normal physiological basal calcium exchange or heart muscle contractility. Additionally, the compound exhibits central antihistaminic and mild dopamine-dampening properties, which contribute to its therapeutic activity in controlling vestibular excitation and neurovascular headache cascades.

How it’s absorbed and eliminated

Following oral administration, flunarizine is rapidly absorbed through the gastrointestinal tract, reaching peak plasma concentration within 2 to 4 hours. The drug is highly lipophilic and binds extensively to circulating plasma proteins (exceeding 99%). It accumulates significantly in adipose tissue and structural cellular membranes upon repeated daily dosing. Hepatic metabolism occurs predominantly via CYP-mediated pathways. Owing to extensive tissue binding, the terminal elimination half-life is remarkably prolonged, ranging from several days after acute exposure up to 3 to 4 weeks following chronic therapeutic dosing. Steady-state plasma concentrations are typically achieved after several weeks of continuous administration.

Indications and Dosing

What it’s used for

The primary established indication for flunarizine is the prophylactic treatment of classic (migraine with aura) and common (migraine without aura) migraine headaches in adult patients. It is designed to reduce the frequency and intensity of migraine attacks rather than to abort an acute attack once initiated. A secondary clinical indication includes the symptomatic management of vestibular vertigo resulting from diagnosed functional disorders of the vestibular system, such as labyrinthine dysfunction or Meniere-like syndromes. Off-label use: In select clinical contexts outside routine guidelines, flunarizine has been evaluated as an adjunctive add-on therapy for treatment-resistant epilepsy; however, this application is strictly considered off-label and requires specialized neurological supervision.

Dosing schedule

For migraine prophylaxis in adult patients aged 18 to 64 years, the standard initial dosage is 10 mg administered orally once daily at bedtime. In geriatric patients aged 65 years or older, the recommended initial dosage is reduced to 5 mg once daily at bedtime to diminish the risk of extrapyramidal and sedative side effects. If satisfactory clinical response is achieved after initial therapy, maintenance therapy may involve dose reduction or an intermittent dosing schedule, such as administering the medication 5 consecutive days per week followed by 2 drug-free days. Clinical efficacy must be reassessed periodically; if no meaningful reduction in migraine frequency is observed after 2 months of continuous administration, treatment should be discontinued.

Safety Profile and Clinical Considerations

Precautions and Adverse Effects

Adverse reactions

Somnolence and daytime sedation represent the most frequently reported adverse effects during the initiation of flunarizine therapy. Weight gain and increased appetite occur commonly during sustained treatment, requiring dietary management. Central nervous system adverse events include extrapyramidal symptoms such as drug-induced parkinsonism (bradykinesia, tremor, muscle rigidity), akathisia, and facial dyskinesia, which occur predominantly in elderly individuals or after prolonged usage. Depressive symptoms and clinical depression have also been reported, occasionally emerging after several months of therapy. Gastrointestinal disturbances, including heartburn and nausea, occur infrequently.

Compatibility with other medicines

Concomitant administration of flunarizine with central nervous system depressants–including sedatives, hypnotics, tranquilizers, opioid analgesics, and alcohol–leads to pronounced additive psychomotor depression and somnolence. Concurrent use with antihypertensive agents may result in additive hypotensive effects, although flunarizine possesses minimal systemic vasodilatory action compared to peripheral calcium blockers. Co-administration with oral contraceptives has been associated with galactorrhea in a small subset of female patients. Steady-state hepatic metabolism may be altered by potent enzyme inducers or inhibitors.

Important precautions

Flunarizine is strictly contraindicated in patients with a history of pre-existing depressive disorders, as well as those with established Parkinson’s disease or other extrapyramidal movement disorders. Baseline medical evaluations should include assessment of motor function and mental state. Treatment must be immediately re-evaluated or stopped if depressive symptoms manifest or if motor signs consistent with extrapyramidal dysfunction develop. Periodic monitoring is recommended during long-term maintenance therapy.

Red flags

Patients and caregivers should be vigilant for critical signs requiring immediate medical intervention. Red flag symptoms include the rapid onset of severe motor stiffness, involuntary rolling movements of the tongue or face, severe unsteadiness causing falls, profound depressive mood changes accompanied by suicidal thoughts, or symptoms indicative of a severe acute hypersensitivity reaction, such as facial swelling, hives, or difficulty breathing.

If you skip a dose

If a daily dose is missed at the intended bedtime, the patient should skip the missed dose entirely and resume treatment at the regular scheduled time the following evening. Patients must not administer a double dose or take an extra tablet during the day to compensate for a missed dose, as this increases the likelihood of excessive daytime sedation and cumulative adverse effects.

Pregnancy, breastfeeding, and other groups

Clinical safety data regarding the use of flunarizine in pregnant women are limited. Animal reproductive studies have not demonstrated direct teratogenic actions, but routine use during pregnancy is avoided unless potential therapeutic benefits clearly justify potential risks to the fetus. Flunarizine is excreted into human breast milk; primary medical guidance advises against breastfeeding while receiving treatment. Safety and efficacy parameters in pediatric populations have not been firmly established for general use.

Storage and expiration

Store this medication at controlled room temperature between 59°F and 77°F (15°C to 25°C). Keep the product inside its original outer packaging to protect the contents from direct light and moisture exposure. Store in a secure location out of reach and sight of children. Do not utilize the medication beyond the printed expiration date indicated on the primary blister pack or bottle label.

Frequently Asked Questions

How long does it take for Sibelium to show preventive effects in migraine management?

Flunarizine is a long-acting prophylactic agent that requires several weeks of continuous daily administration to reach steady-state tissue levels. Patients usually observe a gradual reduction in migraine frequency within 2 to 4 weeks of starting treatment, with maximal therapeutic benefit becoming evident after 4 to 8 weeks. It is not designed to stop acute migraine attacks.

Is it safe to drive or operate machinery while taking this medication?

Because flunarizine commonly causes drowsiness and delayed reaction times, particularly during the first few weeks of therapy, patients should exercise caution when driving, operating machinery, or performing hazardous activities until their individual response and level of alertness have been clearly evaluated.

What should be done if mood changes or persistent sadness occur during treatment?

Depressive mood changes can develop during flunarizine therapy. If a patient experiences unusual sadness, lack of motivation, or depressive symptoms, they should report these changes to their healthcare provider promptly. In such cases, discontinuation of the medication under medical guidance is typically required.

Why is Sibelium recommended to be taken specifically at bedtime?

Administering flunarizine at bedtime aligns with its pharmacokinetic profile and minimizes the functional disruption caused by daytime somnolence. Bedtime dosing allows peak sedative effects to occur during sleep hours, improving overall daytime tolerance.

How does flunarizine differ from calcium channel blockers used for high blood pressure?

While blood pressure medications like amlodipine target peripheral vascular smooth muscle to relax blood vessels, flunarizine is a selective cellular calcium entry blocker that acts centrally on neuronal tissue to prevent cellular calcium overload under ischemic conditions, exerting minimal direct effect on systemic blood pressure.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional. Dispensed in accordance with applicable federal and state regulations.

Additional information
Dosage

5 mg

,

10 mg

Package

30 tabs

,

60 tabs

,

90 tabs

,

120 tabs

,

180 tabs

Ενεργός Ουσία